GILEAD SCIENCES, INC. — Form SCHEDULE 13D/A
Filed August 7, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Gilead Sciences and Arcus Biosciences executed an Amended and Restated Investor Rights Agreement on August 5, 2026, superseding prior agreements dated May 27, 2020, October 11, 2022, and January 29, 2024. The agreement governs Gilead's ownership of Arcus common stock acquired under a separate Common Stock Purchase Agreement and establishes registration rights, lock-up periods, transfer restrictions, and market stand-off obligations tied to Gilead's investment in Arcus. Specific dollar amounts, share counts, and ownership percentages are redacted ([***]) throughout the filing.
Why this rating
Routine amendment to existing investor agreement; Arcus is private/pre-IPO. Gilead's ~$103B market cap dwarfs any single private investment. Standard governance mechanics only.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.